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Intravenous haloperidol has been associated with torsades de pointes (TdP). These two sudden deaths were probable adverse drug
reactions (ADRs) following intramuscular (IM) antipsychotics. The autopsies described lack of heart pathology and were highly
compatible with the possibility of TdP in the absence of risk factors other than the accumulation of antipsychotics with a high
serum peak after the last injection, leading to death within hours. The first case was a 27-year-old African-American male with
schizophrenia but no medical issues. His death was probably caused by repeated IM haloperidol injections of 10mg (totaling 35mg
in 2 days).The second case involves a 42-year-old African-American female with metabolic syndrome. Her probable cause of death
was the last ziprasidone IM injection of 20mg in addition to (1) three extra haloperidol doses (2 hours before the ziprasidone
injection, 5mg oral haloperidol; approximately 21 hours earlier, 5mg oral haloperidol; and 2 days prior, one 10mg IM haloperidol
injection), (2) 10mg/day of scheduled oral haloperidol for 6 days before death, and (3) a long-acting paliperidone injection of
156mg 18 days before death. The study of haloperidol glucuronidation and its impairment in some African-Americans is urgently
recommended.
1. Introduction
Thioridazine was introduced in the US market in 1959 [1]. In
1964 [2], Kelly et al. reported that thioridazine was associated
with quinidine-like electrocardiogram (EKG) abnormalities
in 28 patients and with two cases of ventricular tachycar-
dia leading to death in patients taking 1500mg/day and
3600mg/day, respectively. The awareness of these deaths
before publication led the pharmaceutical company to talk to
Ban and St. Jean [3]. Ban proposed completing a prospective
EKG study using four doses of thioridazine and four doses
of chlorpromazine and trifluoperazine as controls. EKG
abnormalities resembling those caused by quinidine and
hypokalemiawere present in all 6 patients taking thioridazine
(versus 3/6 for chlorpromazine and 1/6 for trifluoperazine)
[3]. Before Ban and St. Jean published their study, Desautels
et al. identified a patientwho survived ventricular tachycardia
while receiving 1500mg/day of thioridazine for 6 weeks [4].
Some other studies were published regarding the matter [1],
including one by Simpson as senior author [5] describing
thioridazine-induced EKG changes as very likely in the
elderly and, therefore, recommending against thioridazine
as a drug for the elderly. According to Shorter, Ban tried
to convince the pharmaceutical company of the clinical
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relevance of thioridazine-induced arrhythmias but was not
successful [1]. As amatter of fact, the company did not change
the prescribing information to warn physicians of the risk
of thioridazine causing torsades de pointes (TdP) until 2000
[1]. Finally, in 2006, more than 40 years after the first deaths
associated with thioridazine, the drug was withdrawn from
the US market [6].
After slowly increasing awareness, the relationship
between drugs, including antipsychotics, and TdP, a poten-
tially lethal adverse drug reaction (ADR), became irrefutable
in the 1990s and the US Food and Drug Administration
(FDA) had no choice but to intervene. The turning point
came in 1996 [7]. Terfenadine was a second-generation
antihistamine that had been approved in the USA in 1985 [6]
after no systematic studies on drug-drug interactions (DDIs)
and on drug metabolism. The randomized controlled trials
(RCTs) in healthy subjects with limited comedication had
demonstrated that it was a very safe drug. Once approved,
terfenadine was widely used in the general population
including in patients who were taking erythromycin,
ketoconazole, and itraconazole. These 3 drugs are powerful
cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors and
terfenadine was metabolized by CYP3A4. In 1996, the FDA
became aware [7] that there were at least 125 deaths in
the US caused by terfenadine. Patients taking any of these
major CYP3A4 inhibitors had major accumulations of
terfenadine with very high serum concentrations leading
to TdP. The FDA required warning labels in the prescribing
information for terfenadine and the CYP3A4 inhibitors;
terfenadine was finally withdrawn from the market in 1998
[6]. The terfenadine deaths explained by DDIs led to the
FDA’s awareness of the need to study CYP metabolism and
DDIs for new drug submissions. The requirements were
progressively increased in the late 1990s, after several other
drugs metabolized by CYP3A4 and with potential to cause
TdP were withdrawn from the market [6].
Sertindole, a second-generation antipsychotic, was intro-
duced in Europe in 1996 [8]. It rapidly became associatedwith
sudden cardiac deaths and an in vitro study demonstrated
that sertindole has high affinity as an antagonist of the cardiac
potassium channel [9]. In humans, the delayed rectifier
potassium current is mediated by the ion channel KCNH2
encoded by the human ether-a-go-go–related gene (HERG)
[9]. After the publication of this article describing that sertin-
dole was an antagonist of the channel encoded by HERG [9],
it became evident that first-generation antipsychotics, such as
thioridazine, must have the same antagonist properties at the
same cardiac channel; this also explained why hypokalemia
is a risk factor for antipsychotic-induced TdP [10].
Since TdP is a very rare event, in the late 1990s the FDA
proposed using prolongation of the QT interval as a TdP risk
marker. This was a complex decision since there is general
agreement that the QT interval needs to be corrected by
heart frequency, which is called corrected QT (QTc), but
there are several formulas for doing it and no agreement
among experts concerning which one is best. Another issue
is how good QTc prolongation proves to be as a sign of
the blockade of the cardiac potassium channel, which is
determined by drug affinity and the serum concentrations in
a specific patient. Thioridazine appears to have the highest
affinity among antipsychotics and the use of very high doses
>1,000mg/day, such as the doses used in the 1960s, led to very
high serum concentrations and extremely high potential for
TdP in many, if not all, patients.
In the late 1990s, the company developing ziprasidonewas
trying to introduce it into the US market, but ziprasidone
has affinity for the human cardiac potassium channels and
caused prolongations of the QTc interval. To allay the FDA’s
concerns, ziprasidone’s marketer decided to complete a mile-
stone prospective randomized study [11] comparing 6 oral
antipsychotics (haloperidol, quetiapine, olanzapine, risperi-
done, thioridazine, and ziprasidone) by themselves and in
the presence of CYP inhibitors (fluvoxamine for CYP1A2,
ketoconazole for CYP3A4, and paroxetine for CYP2D6).
With the specific doses used in that study, thioridazine
was associated with greater QTc prolongations with a mean
increase of 30.1 milliseconds (ms), ziprasidone was second
with 15.9ms, and haloperidol was third with 7.1ms. Following
this study, ziprasidone was permitted in the US market in
2001 with some warnings about QTc prolongation in the
prescribing information. Then, some of the first-generation
antipsychotics started to be withdrawn from some markets
due to TdP risk. This led to major discussions in the US
and international journals [12–14] and major disagreement
on the advertising by the company marketing antipsychotics
about the clinical relevance of antipsychotic-induced QTc
prolongations and the virtues or weaknesses of various
second-generation antipsychotics regarding their effects on
the QTc interval. The problems [14] are that (1) sudden
death on oral antipsychotics has a very low incidence: around
1 in every 10,000 patients. This requires 10,000 patients
taking medications for an extended period to identify a
few cases, making it very difficult to study; and (2) these
large pharmacoepidemiological naturalistic studies include
sudden death cases withmultiple confounding factors and no
guarantee that they are explained by TdP versus other causes
of sudden death or by TdP explained by the combination
of multiple factors besides an antipsychotic. Review articles
started recommending a QTc limit (e.g., >500ms) as a risk
marker for TdP [12]. This became controversial since other
authors recommended other values, such as >450ms [13].
Moreover, the literature clearly indicated that women have
a greater mean QTc; therefore, a sex-corrected QTc limit for
predicting risk for TdP may be needed (e.g., >450ms in men
and >470ms in women) [13].
These controversies concerning QTc prolongation are not
easy to resolve since there is limited reliable data on TdP
cases caused by antipsychotics. Summarizing our current
knowledge [14], we can describe most cases of drug-induced
TdP as occurring in the context of substantial prolongation
of the QTc interval, typically to values >500ms, but QTc
alone is a relatively poor predictor of arrhythmic risk in any
individual patient. Some drugs that substantially prolong the
QTc interval produce very low rates of TdP while others
have much smaller QTc effects but are considerably more
prone to cause TdP [15]. The psychiatric literature describing
clinical cases of TdP is very complex [14], since the cases
are frequently associated with polypharmacy and DDIs, with
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a pharmacodynamic component involving multiple drugs
with HERG channel inhibitory properties and sometimes
a pharmacokinetic component, an inhibitor increasing the
plasma concentrations of one or several of the drugs. Other
risk factors for TdP such as female gender, bradycardia,
hypokalemia, and hypomagnesemia may be important, too
[16].
Since 2001, oral ziprasidone has occasionally been asso-
ciated with TdP, but most of the cases include patients with
other TdP risk factors [17]. A large 1-year mortality study
randomly assigning its 18,000 patients to ziprasidone or
olanzapine concluded that these drugs have similar nonsui-
cide mortality, but the study acknowledged that it did not
have enough power to detect rare events such as TdP [18].
In a comprehensive review of the literature, sponsored by
ziprasidone’s marketer and focused on the company’s RCT
and the postmarketing surveillance data, Camm et al. [19]
concluded that ziprasidone is safe if used as indicated. On
the other hand, amore recent pharmacoepidemiology review
by independent investigators suggested that there were 3
antipsychotics definitively associated with TdP: amisulpride,
haloperidol, and ziprasidone [20]. As population clinical data
[19] and laboratory pharmacological studies [21] indicate that
drug-inducedQTc prolongations are without doubt driven by
higher serum concentrations, the parenteral administration
of any of these antipsychotics, which is associated with
much higher peak concentrations than oral administra-
tion, should substantially increase the risk of antipsychotic-
induced TdP in patients receiving intramuscular (IM) formu-
lations. IM ziprasidone was approved in the US for agitation
in schizophrenia patients in 2002. After a healthy young
Chinesemale patientwith schizophrenia demonstrated aQTc
interval prolongation of 83ms after receiving a single IM
injection with 20mg of ziprasidone, Li et al. [22] completed
a systematic review on the effects of IM ziprasidone on
the QTc interval prolongation. They identified 19 trials in
English or Chinese with a total of 1428 patients, many using
haloperidol IM as a control.Their review identified two cases
of patients who experienced symptoms probably related to
QTc prolongation after IM ziprasidone. If one assumes that
published IM ziprasidone cases are representative, one can
estimate you need only 1,000 patients on IM ziprasidone to
identify symptoms of TdP versus 10,000s required to identify
sudden deaths associated with oral antipsychotics. In the
systematic review, mean QTc change from baseline to end of
each trial ranged from −3.7 to 12.8ms after IM ziprasidone
(compared with −3.5 to 14.7ms on haloperidol IM). Four
RCTs were used to calculate a meta-analysis of QTc interval
prolongation; it showed no significant differences between
IM ziprasidone and IM haloperidol groups. In summary, IM
ziprasidone appeared to have some risk for TdP that did not
look different from IM haloperidol.
The history of haloperidol-induced TdP is also as pro-
tracted as that of thioridazine-induced TdP. Haloperidol is a
first-generation antipsychotic marketed in the 1960s but with
the peculiarity of having formulations for IM and intravenous
(IV) administration that are more risky for TdP since they
provide much higher peak serum concentrations than oral
formulations. IV haloperidol is mainly used for sedation
by internists rather than by psychiatrists and internists
use it in continuous administration controlled by nurses;
there is potential for huge doses since haloperidol is not a
potent drug for sedating patients. Psychiatrists tend to use
haloperidol IM and combine it with other more sedating
drugs (e.g., lorazepam and/or diphenhydramine). During
the 1990s and 2000s, there was a progressive increase in
cases demonstrating the association between extremely high
accumulated doses of haloperidol IV and TdP [23–26],
to the point that the FDA required a warning in the US
haloperidol prescribing information in 2007 [27]. Based on
the case reports of potentially fatal cardiac events, the FDA
warned that haloperidol is not approved for IV adminis-
tration, but if IV administration is used, EKG monitoring
should be performed. Meyer-Masseti et al. [27] considered
the FDA’s recommendations in 2007 confusing. The FDA
warned that QTc prolongation and risk of TdPwere increased
with IV administration of haloperidol or administration of
haloperidol at greater-than-recommended doses in any for-
mulation. However, Meyer-Masseti et al. [27] stressed that
neither the “typical” dosing range nor the minimum dose
associated with these cardiac ADRs was specified in the
haloperidol prescribing information. In their review of the
literature [27], Meyer-Masseti et al. identified a total of 70
cases of IV haloperidol associated with QTc prolongation
and/or TdP. When postevent QTc data were reported, QTc
was prolonged >450ms in 96% of the cases. Most (97%)
of the patients had additional risk factors for TdP, mainly
the coprescription of other proarrhythmic agents. Patients
experiencing haloperidol-associated TdP received a wide
range of cumulative doses from 5mg to 645mg. In their
review, Meyer-Masseti et al. do not address the crucial issue:
what do we know about TdP only caused by IV haloperidol
in the absence of other major risk factors? It is obvious that
IV haloperidol should not be used in patients with TdP risk
factors, but we do not knowwhat doses of IV haloperidolmay
be risky in patients with no known TdP risk factors.
The association between oral and IM haloperidol with
TdP has receivedmuch less attention in the literature than the
association with IV haloperidol. Jackson et al. [28] published
a TdP case associated with 4mg oral haloperidol (2 doses of
2mg separated by 8 hours) in a 66-year-old woman. Harvey
et al. [29] studied 12 volunteers with schizophrenia who were
given a single IM injection of 7.5mg haloperidol or 4mg
lorazepam in a blinded, randomized, placebo-controlled
crossover design. Mean changes in the QTc interval in those
receiving the haloperidol IM dose ranged from 3.6 to 5.1ms,
depending on the formula used to correct for heart frequency.
Harvey et al. [29] concluded that, on average, this dose of IM
haloperidol led to minimal prolongation of the QT interval
and this effect was of theoretical concern in individuals with
risk factors for TdP but seemed unlikely to be a problem in
the vast majority of patients. In our literature searches in
PubMed, we have not been able to identify clinical studies
of QTc prolongation using IM haloperidol formulations with
repeated administration, such as those used by psychiatrists
to control agitation in the clinical environment or case
reports of TdP associated with IM haloperidol. There are IM
ziprasidone RCTs using haloperidol IM as a control, but most
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of the published articles focused on themean increases in QT
prolongation rather than the extreme cases and frequently
considered haloperidol-inducedQTc changes as not clinically
relevant (reviewed in Table 1 of [22]).
In this paper, we present two cases of sudden death after
IM injections of antipsychotics (haloperidol in the first case
and a haloperidol-ziprasidone combination in the second
case) with autopsies indicating lack of heart pathology and
high compatibility with the possibility of TdP. After using
two different ADR scales in each patient [30, 31], the authors
consider these two sudden deaths to be probable ADRs.
2. The Patient Sample That Led to Two Cases
The state of Kentucky is located in the center of the United
States andhas a population of approximately 4million people.
Most Kentuckians are Caucasians; less than 10% are African-
Americans and small numbers of people are from other
racial/ethnic backgrounds. The majority of adult patients
with severe mental illnesses (SMIs) get admitted to 4 state
psychiatric hospitals and 1 forensic facility. According to
our centralized database with admissions data, in the last
15 years the annual number of different patients admitted
to these four psychiatric state hospitals has ranged between
5,556 and 7,106. Our experience with large published studies
[32, 33] in these admitted populations indicates that there
are three main groups of diagnoses justifying admission,
each approximating one-third of the cases: (1) severe mood
disorders, (2) schizophrenia and related psychoses, and (3)
complications of substance use disorders [32, 33].
Since 2002, a state mortality review process has provided
outside review of the deaths at any state facility, in addition to
the internal regulatory process at each facility. The facilities
include not only these state psychiatric hospitals but also
3 nursing homes and 4 long-term care facilities for adults
with intellectual disabilities. Since 2008, some community
deaths have been reviewed as well. Focusing only on deaths
occurring during admission at state psychiatric hospitals
over 14 years (from 2002 to January 2016), we identified 95
deaths. These 95 patients were 63% male and 87% Caucasian
(11% African-American), which roughly corresponds to the
admission demographics in our state psychiatric hospitals,
based on our published studies including thousands of
patients [32, 33]. The mean age of the 95 deceased patients
was 58.0 years (standard deviation 16.7 years), apparently
higher than the average age of admitted patients every year,
which tends to be in the late 30s [32, 33]. Obviously, older
patients are more prone to die. Of these 95 deaths, two
(approximately 2%) appeared highly compatible with TdP
associated with antipsychotic treatment. Both patients were
prescribed high doses of IM antipsychotic injections and had
autopsies showing no heart abnormalities.
According to the committee’s evaluation, besides these 2
deaths compatible with TdP, there were 32 other unexpected
sudden deaths that may need to be considered in differential
diagnosis. Only 7 of these 32 deaths had autopsies but the
committee concluded that (1) 17 appear compatible with
myocardial infarcts, (2) 9 appear compatible with pulmonary
thromboembolism, (3) two appear compatible with sudden
death in the context of epilepsy, (4) one appears compatible
with a rupture of aortic aneurysm, and (5) three were
of unknown origin (including one in which the request
for autopsy was denied by the coroner). An antipsychotic-
induced arrhythmia was not suspected in any of these 32
deaths since they were not temporally associated with recent
IM injections or extremely high doses of oral antipsychotics,
but there is no way of ruling out TdP with 100% certainty. An
autopsy providing another cause of death (e.g., myocardial
infarct) cannot rule out the possibility that the patient had
an antipsychotic-induced TdP on top of a myocardial infarct.
Nonetheless, the two cases described in detail in this paper
were judged to be highly compatible with sudden death after
the high doses of IM antipsychotics in the absence of other
known risk factors for TdP.
3. Case Presentations
3.1. Case 1
3.1.1. Prior History. This patient was a 27-year-old African-
American male. His weight was 88Kg (194 pounds). He had
been diagnosed with chronic schizophrenia since age 22. He
also had a history of polysubstance abuse and was a smoker.
He had 9 prior state hospital admissions. During two of these
admissions, he received one injection of 5mg haloperidol IM
to control psychosis and agitation, each without any obvious
problem. During the 8th admission, he intermittently refused
oral antipsychotic treatment medication that was court-
ordered, which led to 2 injections of 10mg haloperidol
(and diphenhydramine 50mg) without any problem, but
the second injection was administered 3 days later, when
the peak concentrations from the first injection were long
gone. During the 9th admission, when he was 25 years
old, an EKG showed “sinus bradycardia” (frequency of 58
beats per minute). The QT interval was read as 376ms and
the QTc as 373ms. At that time he was taking, as oral
medications, risperidone 4mg/day, benztropine 2mg/day,
and divalproex sodium 1500mg/day and 3 days before the
EKG, the patient had also received an injection of long-acting
risperidone of 37.5mg but no other antipsychotic injections
in the prior week. Three days before the EKG, electrolytes
including potassium were normal. In summary, this EKG
during reasonable doses of oral and long-acting risperidone
demonstrated a completely normal QTc two years before the
patient’s death.
3.1.2. Last Admission. The patient’s 10th admission to state
facilities lasted less than 3 days due to his death in the
early morning of the third day. It was an involuntary
admission with forced medication approved by the court.
The patient was transferred from jail where he had had
no access to tobacco smoking for weeks. Upon arrival,
he was uncooperative and psychotic. His oral medications,
risperidone 6mg/day (3mg twice a day) and benztropine
2mg/day (1mg twice a day), were reordered since it appeared
that he had not been taking them in jail. A court-approved
forced intramuscular (IM) order of haloperidol 10mg and
diphenhydramine 50mg was to be administered if he refused
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any dose of oral risperidone. The admitting psychiatrist was
questioned about this high haloperidol IM dose after the
patient’s death and provided the explanation that 3 years
prior, at the same facility (his 8th admission to a state
facility), the patient had received the same IM dosage of
haloperidol 10mg IM and diphenhydramine 50mg without
problems when refusing court-ordered oral medications.The
psychiatrist was not aware that only 2 such injections were
given during that prior admission and they were separated by
3 days. At admission the patient was uncooperative, refused
a physical exam, and only cooperated with the measure of
blood pressure (130/90mm of Hg) and pulse (106 beats per
minute). During the rest of the admission, he refused offers of
completing the physical exam, vital signs and laboratory tests,
but the available information indicated no obvious medical
problems and he was essentially a medically healthy young
man with no history of any serious medical problems during
his 9 prior admissions to our facilities.
During the first 2 days of this admission, the patient
refused all oral medications and received forced IM med-
ication twice a day with total accumulated dosages of IM
haloperidol 35mg and diphenhydramine 200mg.The patient
received 4 IM haloperidol injections but one of the nurses
made a mistake, giving only 5mg. Therefore, the patient
received 3 injections of 10mg and 1 of 5mg, making a
total of 35mg/day in 2 days. On the second day, partic-
ularly, he received a set of injections with dosages of IM
haloperidol 10mg and diphenhydramine 50mg in the early
a.m. and another set at night. Eighteen minutes after the
night injection, a staff member checking the room reported
that the patient displayed leg movements and 15 minutes
later (33 minutes after the haloperidol injection) he was
found unresponsive. Cardiopulmonary resuscitation (CPR)
was started but the automated external defibrillator (AED)
advised no shock. The emergency medical service (EMS)
arrived, pronouncing the patient dead 1 hour and 13 minutes
after the last haloperidol IM injection of 10mg.
3.1.3. Autopsy. The autopsy showed no obvious anomalies in
the heart or other organs that would explain the patient’s sud-
den death. In macroscopic andmicroscopic examination, the
coronary arteries and myocardium were essentially normal.
3.1.4. ADR Scales. Using the Liverpool ADR Causality
Assessment Tool [30], haloperidol-induced sudden death
after 4 haloperidol IM injections with an accumulated dose
of 35mg in 2 days was deemed probable. The patient had
not taken any other antipsychotic for weeks. Similarly, based
on the Naranjo scale [31], a score of positive 6 (+6) was
determined (scoring +1 on items 1, 5, 8, and 10 and +2 on item
2), consistent with a probable ADR. All authors agreed with
the scores on both ADR scales. As the patient had no signs
of myocardial ischemia or pulmonary thromboembolism, it
appears to the authors that haloperidol had to cause the
sudden unexpected death by TdP after the accumulation
of high serum haloperidol concentrations, particularly with
the fourth and last IM injection. The possible contribution
of diphenhydramine to this case and to the second case is
discussed in detail in the Discussion (see Section 4.5).
As far as we can tell, the literature typically describes
TdP as short-duration phenomena (usually seconds)with two
outcomes: (1) death due to cardiac arrest or (2) disappearance
but with substantial risk of recurrence [34, 35]. Therefore, it
may not be not surprising that the AED did not recommend
an electrical shock which may suggest that TdP was not
present at the time CPR was initiated in this patient. We do
not know how long the patient had been unconscious or in
cardiac arrest; we only know that his unconsciousness was
identified 33 minutes after the last haloperidol IM injection.
3.2. Case 2
3.2.1. Prior History. This patient was a 42-year-old African-
American female who had given birth to one son. She had
been diagnosed with chronic schizophrenia since age 18 and
had 8 prior admissions to Kentucky state psychiatric facilities.
The court had previously declared her legally incompetent
and a sister was appointed to make decisions for her.
However, in Kentucky, guardians cannot involuntarily admit
patients to psychiatric hospitals; a court needs to approve
these admissions.
3.2.2. Last Admission. The patient’s 9th admission to a state
psychiatric facility was precipitated by the worsening of
her psychotic behavior. She was taken to the emergency
room in a university hospital with short-term beds under
an involuntary order allowing a 72-hour examination before
deciding whether or not to ask a court for an involuntary
psychiatric admission. After the filing of court documents for
an involuntary admission, shewas transferred to a psychiatric
state hospital. The admission lasted a total of 7 days until her
death. She stayed 4 days in the emergency room and 3 days at
the psychiatric hospital.
The psychiatric diagnosis was chronic paranoid
schizophrenia. Her medical diagnoses included obesity,
diabetes mellitus type 2, hypertension, hyperlipidemia,
asthma, gastroesophageal reflux disease (GERD), seasonal
allergy, and valproate-induced alopecia. Her weight was
131.5 kg (290 pounds) and her body mass index 45.5. At the
emergency room, the sister reported that the patient was
taking divalproex sodium 1000mg/day (500mg twice a day)
and paliperidone palmitate injections. The sister explained
that divalproex sodium had recently been changed to
topiramate due to alopecia, but this change had not yet been
implemented; moreover, the patient had been noncompliant
with the medication at home. The community mental health
center providing outpatient treatment reported that the
patient had received paliperidone palmitate 156mg every
month for 2 years with the last injection 16 days before the
admission. Her medical medications were, for diabetes,
insulin glargine 10 units/day and metformin 2000mg/day
(1000mg twice a day); for hypertension, lisinopril 5mg/day;
and for allergies, loratadine 10mg/day.
In the emergency room, she was paranoid, tried to hit the
admitting psychiatrist, and showed bizarre behaviors, disrob-
ing and defecating on the bathroom floor. A 5mg haloperidol
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IM injection was given and oral psychiatric medication was
started, including oral haloperidol, 10mg/day (5mg twice a
day), and divalproex sodium, 1000mg/day (500mg twice a
day). The admitting psychiatrist also wrote an “as-needed”
oral order for agitation and/or aggression combining 5mg
haloperidol, 2mg lorazepam, and 25mg diphenhydramine.
These three combined oral drugs (or a single oral drug)
could be administered at the discretion of the nurses but
with a frequency of not more than every 6 hours. For her
medical problems, a diet for diabetic patients was started and
aspirin 81mg/daywas added to her priormedicalmedications
(insulin glargine, 10 units/day; metformin, 2000mg/day;
lisinopril, 5mg/day; and loratadine, 10mg/day). An EKG
on admission (first day at the emergency room after a
haloperidol 5mg IM injection) revealed QT of 336ms, QTc
of 457ms, and sinus tachycardia (frequency of 111 beats per
minute). The routine blood laboratory analyses on the day of
admission showed normal electrolytes but presented several
abnormalities including glucose of 472mg/dL (normal range
65–110), white blood cell count of 11,700 leukocytes/mm3
(normal range 4,100–10,800), neutrophil count of 7,900
neutrophil/mm3 (normal range 1,700–6,000), platelet count
of 503,000 platelets/mm3 (normal range 140,000–370,000),
and glycosylated hemoglobin at 10.4% (normal range 4.8–
5.9). Her valproic acid level was undetectable (<3 𝜇g/mL).
Her urine showed high glucose, moderate ketones, a few
epithelial cells and traces of bacteria. In summary, the labora-
tory abnormalities suggested that she had not been compliant
with her valproate or her antidiabetic medication.Three days
later, some of the abnormal levels were reduced: glucose was
330mg/dL, white blood cell count of 11,740 leukocytes/mm3,
neutrophil count of 4,500 neutrophil/mm3 (a normal value),
and platelet count of 497,000 platelets/mm3. A lipid profile
showed normal values for triglycerides, 133mg/dL (range 35–
150), for cholesterol, 175mg/dL (range 105–200), and for high
density lipoproteins, 37mg/dL but an elevated low density
lipoprotein of 112mg/dL (range 0–99).
At the psychiatric hospital, the patient was very agitated,
psychotic, paranoid, and uncooperative. She would try to
walk into other patients’ rooms, including male rooms, and
touch staff and other patients. These behaviors could not be
controlled by having one staff member closely watching her,
since she did not listen to redirection. In the state psychiatric
hospital over the 3-day period, the antipsychotic dosage pro-
gressively accumulated in addition to the divalproex sodium,
1000mg/day. On day 3 before her death, she received 10mg of
scheduled oral haloperidol and an extra IM injection of 10mg
of haloperidol (with 2mg IM lorazepam). On day 2 before
her death, she received 10mg of scheduled oral haloperidol.
In the early morning (5 AM), she received an extra oral
combination of 5mg of haloperidol, 2mg of lorazepam, and
25mg of diphenhydramine. At night, she was agitated and
trying to get into the rooms of other patients and at 11 PM
she again received extra oral doses of 5mg of haloperidol,
2mg of lorazepam, and 25mg of diphenhydramine. Forty-
five minutes later, as she still could not sleep, she was given
50mg of oral hydroxyzine pamoate. Shortly thereafter, on the
third day of admission, in the early AM, the psychiatrist on
call was contacted because the patient continued exhibiting
the same behaviors and could not receive another haloperidol
dose until 6 hours had passed; the psychiatrist ordered the
combination of 2 IM injections, 20mg IM of ziprasidone and
25mg diphenhydramine at 1:19 AM (2 hours and 19 minutes
after the last extra dose of oral haloperidol). Finally, at 2:20
AM she was described as resting quietly in her room. At 7:15
AM, when staff asked if the patient wanted breakfast, she
opened her eyes and responded with a gesture that she did
not want it and went back to sleep. At 9:00 AM her breathing
sounded abnormal to a staff member, who called for a nurse;
the nurse found the patient unresponsive with no radial pulse
and a faint carotid pulse. This was 7 hours and 41 minutes
after the 20mg ziprasidone IM injection and approximately
10 hours after the last extra dose of oral haloperidol. CPR was
started but the AED advised no shock. The EMS arrived and
found her in asystole, so at 9:40 AM the patient was declared
dead.
3.2.3. Autopsy. The autopsy revealed no obvious anomalies
in the heart or other organs that would explain the patient’s
sudden death. It is important to stress that in spite of her
metabolic syndrome, there were no signs of atherosclerosis
in the coronary arteries nor any sign of myocardial ischemia
in macroscopic or microscopic examinations. There was
no evidence of pulmonary thromboembolism. There were
some minor abnormalities including mild atherosclerosis
at the thoracoabdominal aorta, liver changes compatible
with a fatty liver, and a small thyroid mass that micro-
scopic examination demonstrated to be a follicular neo-
plasm. Postmortem blood toxicology for diphenhydramine
was 172 ng/mL (reference range: 30–300 ng/mL) and for
hydroxyzinewas 35.4 ng/mL (reference range: 22–80 ng/mL).
3.2.4. ADR Scales. Using the Liverpool ADR Causality
Assessment Tool [30], antipsychotic-induced sudden death
was deemed probable. The last ziprasidone IM injection
of 20mg was considered crucial, because it was given in
addition to (1) three extra haloperidol doses (approximately
2 hrs before the ziprasidone injection, 5mg oral haloperidol;
approximately 21 hours earlier, 5mg oral haloperidol; and
2 days before, one 10mg IM haloperidol), (2) 10mg/day
of scheduled oral haloperidol for 6 days prior to death,
and (3) a long-acting paliperidone injection of 156mg 18
days prior to death. Similarly, on the Naranjo scale [31],
a score of +6 was determined (scoring +1 on items 1, 5,
8, and 10 and +2 on item 2), consistent with a probable
ADR. All the authors agreed with the scores on both
ADR scales. As the patient had no signs of myocardial
ischemia or pulmonary thromboembolism, it appears that
the combination of antipsychotics, including the addition of
IM ziprasidone on top of IM haloperidol, oral haloperidol,
and long-acting paliperidone caused the sudden, unexpected
death by TdP. The ziprasidone peak from the IM injection
probably combined with the slower peak of the extra oral
haloperidol administered 2 hours earlier causing the TdP
early the following morning. Oral absorption is much slower
than IM absorption and the oral haloperidol absorption
Case Reports in Psychiatry 7
may have been further delayed by the combination of an
antimuscarinic drug, diphenhydramine.
The possible contribution of diphenhydramine to this
case and to the first case is discussed in detail in the
Discussion (see Section 4.5).
4. Discussion
4.1. Limitations of the Patient Sample. To identify these 2
sudden deaths, possibly explained by TdP associated with
antipsychotics, we started with 95 deaths reviewed retrospec-
tively using the judgment of a committee composed of psy-
chiatrists, nurses, and pharmacists who have expertise in the
subject. During the committee’s 13 years of reviewing deaths,
judgments regarding the medical cause of death were made
after discussion by 2 or 3 psychiatrists whowere present at the
meetings. The senior author was involved in all reviews of all
patients and attended all meetings.We know that the weakest
part of our reviews is the limited number of autopsies, 17%
(16/95). For years, we have encouraged their use, but we
have not been too successful in increasing their numbers,
particularly due to cost. We were fortunate to have autopsies
of these 2 cases that were highly compatible with TdP. Even
with all the limitations of our retrospective reviews, we have
accumulated substantial experience with >500 deaths in our
state facilities and >350 deaths of psychiatric patients in the
community.
4.2. Limitations of the Case Reports. It is difficult to make
causal connections in case reports. Both deaths were sudden
and unexpected, with no signs of cardiac ischemia in the
autopsies. They were, however, associated with the accu-
mulation of high serum antipsychotic concentrations after
IM injections, compatible with probable ADRs, according
to the scales. There are other rare causes of sudden death
(e.g., genetic long QT syndrome, Brugada syndrome, or
catecholaminergic polymorphic ventricular tachycardia) that
cannot be completely ruled out [36], but the proximity of
the high doses of IM antipsychotics and the lack of known
family histories of sudden deaths in both patients suggested
that these two sudden deaths were most likely explained
by antipsychotic-induced TdP. Electrolyte abnormalities may
contribute to TdP. The first patient refused laboratory testing
but was a healthy young male and the second patient did
not have any electrolyte abnormality, although magnesium
is not routinely measured in our hospitals. In summary, a
reasonable interpretation is that these two sudden deaths
were unfortunate cases of TdP secondary to the accumulation
of high serum peaks of antipsychotics after the last IM
injection.
Sinus bradycardia is a risk factor for TdP [16]. The first
patient had an EKG with sinus bradycardia 2 years before
his death. The EKG described a frequency of 58 beats per
minute which appears to be mild bradycardia to us. We do
not know if he had sinus bradycardia at any time during the
admission leading to his death since the patient refused EKG
and vital signs except at the time of admission when he was
tachycardic. It is possible that a sinus bradycardia may have
contributed to the development of TdP in the first case but we
have no way to prove or disprove it.
4.3. African-American Race. Knowing that less than 10%
of our patients are African-American, we were surprised
that both of these deceased patients were African-American.
If we assume a frequency of 10% among our patients at
psychiatric hospitals in Kentucky, the chance probability
that one deceased patient is African-American is 0.10. The
chance probability that both are African-Americans is very
low: 0.01 (obtained by multiplying 0.10 by 0.10). This is
lower than the typical set value of 𝑝 < 0.05 and suggests
that the association of African-American race with 100%
(2/2) of the antipsychotic-induced sudden deaths may not be
explained by chance. We also formally tested the hypothesis
of the association between African-American race and TdP
by using as a control the prevalence of African-Americans
in sudden deaths not compatible with TdP. A 2-sided Fisher
exact test provided a significant difference (𝑝 = 0.016)
when comparing 100% (2/2) of African-Americans in sudden
deaths compatible with TdP versus 7.5% (2/26) of African-
Americans in sudden deaths that were not considered to be
explained by TdP and in which the race was known.
In spite of the very small sample size of 2 deaths, both
tests of significance were compatible with the possibility that
African-American patients may havemore risk of death from
antipsychotic-induced TdP in our sample. Let us for the
moment assume that, as a matter of fact, African-Americans
may have a higher risk of dying in our psychiatric hospitals
by antipsychotic-induced TdP. Is there any pharmacological
mechanism that may explain this association? Yes, there is
one; it is the possibility that African-Americans are prone
to a higher prevalence of being poor metabolizers (PMs) of
haloperidol. Haloperidol metabolism has never been system-
atically studied to the extent that new drugs are currently
studied before they are introduced in the US market. This is
important because some old antiepileptics were found to have
completely unexpected pharmacokinetic properties when
intensively studied prior to introduction in the US market in
the 2000s [37]. Psychiatric textbooks and review articles [38]
usually indicate that CYP2D6 PMs have decreased ability to
eliminate haloperidol. A study of 31 subjects taking haloperi-
dol as a baseline for a clozapine RCT provided an unexpected
result [39]. The persistence of serum haloperidol concentra-
tions after haloperidol discontinuation was used to calculate
haloperidol elimination half-life in each patient as an approx-
imated marker of haloperidol metabolism. After eliminating
patients who had taken haloperidol decanoate, there were a
total of 26 patients, of which 16 patients had a half-life <3
days, suggestive of relatively normal haloperidol metabolism,
and 10 patients had a half-life ≥3 days, compatible with
being haloperidol PMs. Not surprisingly, the only 2 CYP2D6
PMs were in the group with a half-life ≥3 days, suggesting
that, in effect, not having CYP2D6 impairs one’s ability
to eliminate haloperidol. Unexpectedly, the only significant
difference (with a 𝑝 = 0.014) between the 16 haloperidol
normalmetabolizers and the 10 haloperidol PMswas that all 4
African-Americans were haloperidol PMs and had half-lives
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≥3 days (as a matter of fact, all 4 patients had half-lives >7
days) [39]. As haloperidol is at least partly metabolized by
glucuronidation and some of the glucuronidation enzymes
have lower activity in African-Americans [40], it is possible
to hypothesize that some African-Americans may have lower
ability to eliminate haloperidol due to decreased activity in
haloperidol glucuronidation. Recently, an in vitro study of
haloperidol metabolism using human hepatocytes has sug-
gested that the uridine diphosphate glucuronosyltransferase
(UGT) 2B7 (UGT2B7) may be important in the metabolism
of haloperidol [41]. Although there is substantial variation of
UGT2B7 allelesworldwide [42], the clinical relevance of these
genetic variations for people with African ancestry is not
known [43]. In summary, there is very limited information on
haloperidol metabolism, but it is possible that some African-
Americans may have impaired ability to eliminate haloperi-
dol. If our two patients had impaired ability to eliminate
haloperidol, that impairment may have contributed to higher
serum haloperidol concentrations, leading to greater risk for
TdP. As the haloperidol serum concentration level increases,
the blockade of cardiac potassium channels would likewise
increase.
4.4. Accumulation of One or Several Antipsychotic Formula-
tions. We think that, in these two patients, the last antipsy-
chotic IM injection served as “the straw that broke the
camel’s back” by providing an even higher peak in serum
antipsychotic concentration which contributed to further
blockade of cardiac potassium channels encoded by HERG
reaching a very high level, leading to TdP. In the first patient,
this was achieved after 4 haloperidol IM injections with an
accumulated dosage of 25mg in 2 days before the fourth and
last injection of 10mg, making a total of 35mg. In the second
patient, it was achieved after the last ziprasidone IM injection
of 20mg in addition to (1) three extra haloperidol doses
(approximately 2 hours before the ziprasidone injection, 5mg
oral haloperidol; approximately 21 hours earlier, 5mg oral
haloperidol; and 2 days before, one 10mg IM haloperidol),
(2) 10mg/day of scheduled oral haloperidol for 6 days prior
to death, and (3) a long-acting paliperidone injection of
156mg 18 days prior to death. The second patient received
5mg oral haloperidol at 11 PM; therefore, the nurse could
not administer another as-needed haloperidol dose until
5 AM the next morning and called the psychiatrist on
call. In retrospect, we think that the on-call psychiatrist
who responded to the nurse and prescribed 20mg IM of
ziprasidone at 1:19 AM on top of the prior extra dose of
oral haloperidol made a huge mistake. Both ziprasidone and
haloperidol appear to be potent blockers of cardiac potassium
channels in clinical doses [11]. Therefore, in this second case,
the effects of ziprasidone blocking the cardiac potassium
channels encoded by HERG were added to the blocking
effects of the prior haloperidol dose. In retrospect, it would
have been better to control the agitation of this patient only
with lorazepam, which has no relevant effects on the QTc
interval [29].
4.5. Comedications in Addition to Antipsychotics. The
only comedication received by the first patient was IM
diphenhydramine. The second patient received, besides
IM diphenhydramine, several medications (valproate, in-
sulin, metformin, lisinopril, lorazepam, and hydroxyzine),
which have not been associated with TdP or relevant QTc
prolongation.
Diphenhydramine has been associated with (1) TdP,
occasionally during voluntary overdoses [44–46]; (2) a strong
signal for TdP in the databases from drug regulatory agencies
[47]; (3) QTc prolongations during voluntary overdoses [48–
52], and (4) QTc prolongations in EKGs completed at the
emergency room when prescribed by itself or with other
drugs that prolong the QTc interval [53]. However, some
of these diphenhydramine overdose studies with EKG data,
including 126 cases of overdoses with no TdP case [48] and 1
case monitored for several days [50], suggested that diphen-
hydramine causes tachycardia and this has a major effect on
protecting from TdP in situations of QTc prolongation.
The accumulated diphenhydramine dosage was 200mg
IM during the last 3 days of Case 1 and 75mg during the
last 2 days of Case 2 (25mg IM 2 days prior to death and
50mg oral on the day before death). We doubt that these
doses of diphenhydramine had any relevance in the sudden
deaths of these two patients because (1) TdP induced by
diphenhydramine overdoses appears to require huge quan-
tities measured in grams [44, 45], (2) diphenhydramine-
induced tachycardia may protect from TdP in situations of
QTc prolongation [48, 50], and (3) some animal models of
clinical relevance in humans for drugs that prolong QTc
cannot detect any effect for diphenhydramine doses trying to
replicate clinical dosing [54].
4.6. Reflections on the History of Antipsychotic-Induced TdP.
The next section discusses a practice guideline limiting high
doses of haloperidol and/or ziprasidone IM injections in the
hope of preventing the repetition of similar TdP cases in
our Kentucky facilities. Ideally, practice guidelines should
be based on principles following the hierarchical thinking
proposed by evidence-based medicine, which gives higher
value to RCTs. In the real world, those researchers insisting
on the evidence-based medicine (EBM) approach are not
aware that evidence related to ADRs is seriously distorted
by the effects of pharmaceutical companies to cover the
ADRs resulting from their drugs and their lack of attention
to ADRs during studies undertaken for market approval
[55]. Moreover, RCTs focus on mean effects, but when a
very rare ADR, such as TdP, is studied, mean values are
irrelevant and outliers are important [56]. Therefore, some
authors can dismiss the risk of haloperidol-induced TdP
because it is mainly based on case reports and not RCT
data [57]. How unwise is it to ask clinicians to wait for
RCT data on haloperidol-induced TdP? It is very unwise;
a randomized study of >18,000 patients followed for 1 year
had no statistical power to detect ziprasidone-induced TdP
[18]. Haloperidol is off-patent; therefore, nobody is going
to finance a large RCT of 10,000s of patients for several
years to detect statistical differences between haloperidol and
other drugs in causing TdP. Imagine that the thioridazine
marketer had paid attention to Ban [1] in the late 1960s,
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performed more studies, and withdrawn thioridazine from
the market instead of waiting until 2006. The outcome of
that decision, based on “limited” case reports would probably
have led to saving hundreds or thousands of lives worldwide
during the last 30 years. Psychiatrists would have prescribed
other antipsychotics with less risk for TdP rather instead of
prescribing thioridazine, whichmay be the oral antipsychotic
that most frequently causes sudden death [58]. Similarly, it
would be a mistake to ignore the risk of TdP associated with
high doses of haloperidol IM, suggested by our 2 case reports.
4.7. Practice Guidelines. Both deaths were considered pos-
sibly preventable if the prescribing psychiatrist had better
understood the risk of a standing as-needed order for agi-
tation using IM antipsychotics with potential to cause TdP.
This type of order is written for all our patients but is rarely
used by nurses. If they are used in a patient, IM antipsychotic
injections are rarely repeated within a few hours. In the
first case, the psychiatrist allowed a high dosage of 10mg
haloperidol IM every 12 hours, which is rarely prescribed
in our hospitals (most psychiatrists prescribe 5mg every 6
hours at most). The psychiatrist thought it was safe because
the same order had been written for the same patient at the
same hospital 3 years before, but 3 years before it was scarcely
used. In the second case, the as-needed order of 5mg every 6
hours was written as administered by the oral route, but when
it was not enough to control the agitation of the patient, the
nurses called the on-call psychiatrist who circumvented the
limit of a haloperidol dose every 6 hours by adding 20mg
IM ziprasidone in close proximity to the last oral dose of
haloperidol.
The medical literature has addressed the risk of TdP
during IV haloperidol treatment, but the psychiatric lit-
erature including practice guidelines [59] has paid little
attention to the risk of TdP after IM haloperidol and/or IM
ziprasidone. Therefore, a practice guideline was developed
for IM antipsychotics to limit dosing for haloperidol and/or
ziprasidone IM in order to prevent future TdP cases and
suddendeaths in our public psychiatric hospitals inKentucky.
The practice guideline that is shown in the Appendix was
based on (1) a comprehensive review of the literature on the
use of IM antipsychotics to treat agitation, including review
articles [60–74] and prior practice guidelines [59, 75–79]; (2)
learning from themistakes in these two cases; and (3) a review
of the pharmacokinetic and pharmacodynamic mechanisms
behind the DDIs contributing to antipsychotic-induced TdP
[14, 80, 81].
5. Conclusion
Themedical literature has addressed the risk of TdPduring IV
haloperidol treatment but the psychiatric literature has paid
little attention to TdP risk after IM haloperidol and/or IM
ziprasidone [59]. In this paper, we presented two cases of sud-
den death after IM injections of antipsychotics, which were
considered to be probable ADRs. The autopsies described
lack of heart pathology and were highly compatible with the
possibility of TdP in the absence of risk factors other than the
accumulation of antipsychotics with an even higher serum
peak after a last injection led to death within a few hours. It
is possible that these cases were explained by a combination
of high serum concentrations of antipsychotics with partic-
ular individual vulnerability. Some studies suggest that rare
genetic variations at potassium channels may contribute to
predisposition to drug-induced TdP [82].
The first case describes a 27-year-old African-American
male with schizophrenia but no medical issues. His death
occurred in the early morning of the third day and was prob-
ably caused by repeated IM haloperidol injections of 10mg
(totaling 35mg in 2 days).The second case involves a 42-year-
old African-American female with a metabolic syndrome.
Her death was probably caused by a last ziprasidone IM injec-
tion of 20mg in addition to (1) three extra haloperidol doses
(approximately 2 hours before the ziprasidone injection, 5mg
oral haloperidol; approximately 21 hours earlier, 5mg oral
haloperidol; and 2 days prior, one 10mg IM haloperidol),
(2) 10mg/day of scheduled oral haloperidol for 6 days prior
to death, and (3) a long-acting paliperidone injection of
156mg 18 days prior to death. The association of TdP deaths
with African-American race in spite of the small sample
size appears to suggest a significant overrepresentation when
compared with our patients at Kentucky public psychiatric
hospitals. As a matter of fact, patients with poor capacity
to metabolize haloperidol might be overrepresented among
African-Americans. The study of haloperidol metabolism
through glucuronidation in African-Americans is urgently
recommended since the percentage of impaired individuals
may be overrepresented in African-American individuals. If
it is demonstrated that African-Americans have lower ability
to metabolize haloperidol, this would indicate the need to
consider race and possibly genetics, in the dosing of IM
antipsychotics for agitation and for the need to include these
differences in the practice guidelines for agitation.
Appendix
Proposed practice guidelines for dosing parenteral antipsy-
chotics in order to avoid TdP during the control of agitation
at psychiatric hospitals are as follows.
IV Haloperidol. The use of IV haloperidol is not recom-
mended and it cannot be used unless continuous EKG
monitoring is available.
IM Chlorpromazine. The use of IM chlorpromazine is not
recommended because of the lack of studies and very limited
number of RCTs [60] and the potential for oral chlorpro-
mazine to cause TdP and orthostatic hypotension [61]. IM
chlorpromazine cannot be used unless there is (1) an absence
of any of the risk factors for TdP (see below) and (2) a baseline
EKG that shows QTc < 450ms on the same medication that
the patient is currently taking.
Combining IM Haloperidol and IM Ziprasidone. Orders for
IM haloperidol and IM ziprasidone cannot be combined in
the same patient. If a patient has received IM haloperidol,
no IM ziprasidone can be administered for 24 hours and if
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a patient has received IM ziprasidone, no IM haloperidol can
be administered for 24 hours.
IM Haloperidol
(1) IM Haloperidol cannot be used in any patient with
risk factors for TdP (see below).
(2) Standard agitation as-needed orders for IM haloperi-
dol doses ≥10mg cannot be written unless there is
a baseline EKG that shows QTc < 450ms on the
same medication that the patient is currently taking.
See below for an exception for patients on potent
inducers.
(3) Standard agitation as-needed orders for IM haloperi-
dol doses of 5mg should not recommend adminis-
tration with a frequency <12 hours unless there is
a baseline EKG that shows QTc < 450ms on the
same medication that the patient is currently taking.
The combination of IM haloperidol with IM benzo-
diazepines and/or IM antihistaminic/anticholinergics
has not been systematically studied but is frequently
used by our clinicians. To decrease the total number of
haloperidol doses and reduce the potential for seda-
tion, clinicians are encouraged to combine haloperi-
dol IM injections of 5mg with simultaneous adminis-
tration of a benzodiazepine IM injection (such as IM
lorazepam) and/or IM anticholinergic/antihistamine
injection (such as IM diphenhydramine). As these
latter medications do not appear to be associated with
risk forQTc prolongation, they can be administered at
frequencies of less than 12 hours.
(4) If there is no baseline EKG while on current medica-
tions, it isOK towrite standard orders for agitation for
haloperidol 5mg every 12 hours while using other IM
drugs with less potential for QTc prolongation more
frequently (e.g., for 1mg of lorazepam every 6 hours
and/or for 25mg of diphenhydramine every 6 hours).
(5) Fluoxetine is at least a mild inhibitor of haloperidol
metabolism [81]. In patients taking fluoxetine orwho
have taken it in the last month (norfluoxetine stays in
the body for weeks after discontinuation), clinicians
need to be aware that the doses of haloperidol IM that
they write may produce higher effects. The limited
available published information [81] suggests that
adding fluoxetine is equivalent to increasing serum
haloperidol concentrations by 33% after 12 weeks
on fluoxetine. This is equivalent to multiplying the
effects of the haloperidol IM dose by a factor of
1.33 and to compensate, this will require multiplying
IM haloperidol doses by 0.75 (calculated by dividing
1/1.33 = 0.75). There are no haloperidol studies of
the effects of fluoxetine over several months and at
steady state for inhibition of haloperidol metabolism;
therefore, it is possible that patients taking fluoxetine
may require even lower IM haloperidol doses. It may
be safer to avoid IM haloperidol in patients taking
fluoxetine since fluoxetine also prolongs QTc.
IM Ziprasidone
(1) IMziprasidone cannot be used in any patientwith risk
factors for TdP (see below).
(2) The prescribing information recommends maximum
total daily doses of ≤40mg/day and intervals for
doses of ≥2 hours for 10mg and ≥4 hours for 20mg
injections.
(3) Standard agitation as-needed orders for IM ziprasi-
done of 20mg should not recommend administration
with a frequency of <12 hours unless there is a
baseline EKG that shows QTc < 450ms on the same
medication that the patient is currently taking.
IM Olanzapine
(1) IM olanzapine appears to have less risk for QTc
prolongation than IM haloperidol and/or IM ziprasi-
done. If there is a need for IM antipsychotics in a
patient with risk factors for TdP, olanzapine IM is a
better choice than haloperidol or ziprasidone IM [65].
(2) The olanzapine prescribing information recommends
maximum total daily doses of ≤30mg/day and an
interval for 10mg doses of ≥2 hours after the initial
injection and ≥4 hours after the second IM injection.
(3) Although oral olanzapine is not usually linked to
orthostatic hypotension, IM olanzapine has been
associated with syncope.The prescribing information
recommends doses ≤5mg in geriatric patients (≥65
years) and doses of 2.5mg in patients with risk for
orthostatic hypotension.
(4) IM olanzapine is a fairly sedating drug and there is
no need to combine it with benzodiazepines. As a
matter of fact, it should not be combinedwith IMben-
zodiazepines since this combination has occasionally
been associated with hypotension [71] and even rarely
with death [67].The decision to add an IMolanzapine
injection within 24 hours of a benzodiazepine IM
injection would require chart documentation for the
reason and a written order to closely monitor the
patient for orthostatic hypotension and/or respiratory
depression to avoid any risk, since we have very
limited data about the safety of this combination,
which is discouraged by olanzapine’s marketer [63].
Obviously, if the patient is lying in bed, there is no
need to monitor for orthostatic changes unless the
patient needs to get up.
(5) If the patient is taking fluvoxamine, IM olanzapine
should be used in lower doses due to the inhibition of
olanzapinemetabolism.The clinician should consider
using half the dosage he/she typically uses [14].
IM Aripiprazole
(1) IM aripiprazole appears to have less risk for QTc
prolongation than IM haloperidol and/or IM ziprasi-
done.
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(2) The aripiprazole prescribing information recom-
mends (a) maximum total daily doses of ≤30mg/day,
(b) a dose of 9.75mg (range 5.25–15mg), and (c) and
an interval between injections ≥2 hours.
(3) If the patient is taking powerful CY3PA4 inhibitors or
CYP2D6 inhibitors (including paroxetine and fluoxe-
tine), halving the doses is recommended. Duloxetine
and bupropion are moderate CYP2D6 inhibitors;
therefore, using half the dosage used for typical
patients appears to be a good idea [14].
(4) There is limited information comparing IM aripipra-
zole with other IM second-generation antipsychotics,
but the available information suggests that IM arip-
iprazole may be less effective for controlling agitation
than IM olanzapine or IM ziprasidone [61, 62].
Patients with Risk for TdP. Having any of the following is
considered a risk factor for TdP: (1) history of sudden death
in the family, (2) personal history of syncope, (3) active or
residual serious heart disease, (4) geriatric age (≥65 years),
(5) bradycardia (<60 beats per minute), (6) hypokalemia, (7)
hypomagnesemia, or (7) the use of nonpsychiatric drugs with
risk for QTc prolongation including antiarrhythmics (amio-
darone dofetilide, quinidine, procainamide, and sotalol),
some antibiotics (e.g., gatifloxacin and moxifloxacin), or
others (e.g., arsenic trioxide, mefloquine, methadone, pen-
tamidine, and tacrolimus).
Some of these factors can be easily reversed; therefore,
correcting electrolyte abnormalities or discontinuing drugs
associated with QTc prolongation should be considered
before adding orders for IM antipsychotics. IM benzodi-
azepines do not appear to prolong QTc interval; therefore, it
appears safe to use them in patients with risk for TdP [67].
Patients on Scheduled Antipsychotics or Antidepressants with
Risk for TdP. Some oral antipsychotics (including amisul-
pride, haloperidol, iloperidone, phenothiazines, pimozide, or
ziprasidone), haloperidol decanoate, fluphenazine decanoate,
and antidepressants (including SSRIs and TCAs) have been
definitively associated with clinically relevant potential to
prolong QTc; therefore, it is better to avoid adding IM
haloperidol and IM ziprasidone for agitation in a patient tak-
ing any of these drugs. IM benzodiazepines or IM olanzapine
should be considered for as-needed orders for agitation in
these patients. If the clinician considers the riskier path of
adding IM haloperidol or IM ziprasidone to these psychiatric
medications, he/she needs to consider using lower doses and
provide written justification.
Patients on Inducers. If the patient is on a potent inducer
(e.g., rifampin or some antiepileptic drugs: carbamazepine,
phenytoin, or phenobarbital), he/she may metabolize some
antipsychotics such as aripiprazole, haloperidol, or olanza-
pine very fast [80] and may need higher doses of these
IM antipsychotics beyond what is typically recommended.
If the clinician needs to write higher doses of any of these
IM antipsychotics, he/she should consult the pharmacy first
before writing an order for unusually high doses of any IM
antipsychotics. Potent inducers appear to have small effects
on ziprasidonemetabolism [80]; therefore, although this has
not been studied well, patients taking potent inducers may
respond to normal doses of IM ziprasidone. Normal doses of
ziprasidone IM may be a rational choice for patients taking
potent inducers.
Patients with Alcohol Intake/Intoxication. IM antipsychotics
should be judiciously used to manage agitation in patients
with recent alcohol intake or alcohol intoxication. IM olan-
zapine [71, 72] and IM ziprasidone with or without benzodi-
azepines [70] have been associated with decreases in oxygen
saturation.
Individualized Treatment. This set of guidelines for IM
antipsychotics was developed to discourage the use of high
doses of IM haloperidol, IM ziprasidone, or the combination
of IM haloperidol with IM ziprasidone for standard agitation
orders for all patients. It does not appear safe to continue
to use nurses’ judgment to decide the safe frequency of this
type of order when this appears to have led to two sudden
deaths in our psychiatric hospitals. In emergency situations,
a clinician can overrule the dosing limits in this guideline
by using a one-time order prescribing high doses as long as
he/she understands the risk and has appropriate safeguards
in place (see the IM olanzapine and IM benzodiazepine
combinations) and documents them in the chart. Once the
emergency situation is resolved, the clinician should be ready
to have his/her actions reviewed by the hospital pharmacy
thatmay encourage or discourage similar actions in the future
based on the peculiarities of the individual case.
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